Commentary: FDA too cautious

05/17/2007 | Wall Street Journal, The

The FDA acted outside its authority when it rejected Arcoxia because the company had not proven the drug was superior to one already on the market, a Hoover Institute fellow and an industry consultant write in this Wall Street Journal commentary. The authors say such a stance is too cautious and limits treatment options.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ